ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Doctors Hospital of Laredo, UNM Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3011791997